phase ii clinical trials of idarubicin have indicated that : by i.v . route idarubicin is a potent antileukemic agent active in relapsed or refractory , anll , all ( adult and pediatric ) either as single agent or in combination with ara-c at doses of 8-12 mg/m2 by i.v . day 1 , 2 and 3 or 7-8 mg/m2 i.v . daily x 5 days ( adults ) .
C0020789
idarubicin
C0023467
anll